Literature DB >> 8068955

Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study.

A Butturini1, R P Gale, P C Verlander, B Adler-Brecher, A P Gillio, A D Auerbach.   

Abstract

We analyzed data from 388 subjects with Fanconi anemia reported to the International Fanconi Anemia Registry (IFAR). Of those, 332 developed hematologic abnormalities at a median age of 7 years (range, birth to 31 years). Actuarial risk of developing hematopoietic abnormalities was 98% (95% confidence interval, 93% to 99%) by 40 years of age. Common hematologic abnormalities were thrombocytopenia and pancytopenia. These were often associated with decreased bone marrow (BM) cellularity (75% of cases studied). Clonal cytogenetic abnormalities developed in 23 of 68 persons with BM failure who had adequate studies. Actuarial risk of clonal cytogenetic abnormalities during BM failure was 67% (47% to 87%) by 30 years of age. Fifty-nine subjects developed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Actuarial risk of MDS or AML was 52% (37% to 67%) by 40 years of age. Risk was higher in persons with than in those without a prior clonal cytogenetic abnormality (3% [0% to 9%] v 35% [0% to 79%]; P = .006). One hundred twenty persons died of hematologic causes including BM failure, MDS or AML and treatment related complications. Actuarial risk of death from hematologic causes was 81% (67% to 90%) by 40 years of age.

Entities:  

Mesh:

Year:  1994        PMID: 8068955

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  80 in total

Review 1.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

2.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

3.  DNA crosslinking damage and cancer - a tale of friend and foe.

Authors:  Yaling Huang; Lei Li
Journal:  Transl Cancer Res       Date:  2013-06       Impact factor: 1.241

Review 4.  Molecular pathogenesis of Fanconi anemia.

Authors:  Natalie Collins; Gary M Kupfer
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

5.  Fanconi anemia in infancy: report of hematopoietic stem cell transplantation to a 13-month-old patient.

Authors:  Koichi Oshima; Akira Kikuchi; Shinji Mochizuki; Daisuke Toyama; Naoki Uchisaka; Miharu Yabe; Ryoji Hanada
Journal:  Int J Hematol       Date:  2009-05-19       Impact factor: 2.490

6.  Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia.

Authors:  Richard Mitchell; John E Wagner; Betsy Hirsch; Todd E DeFor; Heather Zierhut; Margaret L MacMillan
Journal:  Br J Haematol       Date:  2013-10-30       Impact factor: 6.998

Review 7.  Fanconi anemia and the underlying causes of genomic instability.

Authors:  Julie Rageul; Hyungjin Kim
Journal:  Environ Mol Mutagen       Date:  2020-02-06       Impact factor: 3.216

8.  HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.

Authors:  Ricardo Pasquini; Jeanette Carreras; Marcelo C Pasquini; Bruce M Camitta; Anders L Fasth; Gregory A Hale; Richard E Harris; Judith C Marsh; Anibal J Robinson; Mei-Jie Zhang; Mary Eapen; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

9.  TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia.

Authors:  Haojian Zhang; David E Kozono; Kevin W O'Connor; Sofia Vidal-Cardenas; Alix Rousseau; Abigail Hamilton; Lisa Moreau; Emily F Gaudiano; Joel Greenberger; Grover Bagby; Jean Soulier; Markus Grompe; Kalindi Parmar; Alan D D'Andrea
Journal:  Cell Stem Cell       Date:  2016-03-24       Impact factor: 24.633

10.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Authors:  P S Becker; J A Taylor; G D Trobridge; X Zhao; B C Beard; S Chien; J Adair; D B Kohn; J E Wagner; A Shimamura; H-P Kiem
Journal:  Gene Ther       Date:  2010-05-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.